
AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint …

AstraZeneca and its biologics R&D arm MedImmune have released a statement admitting that their fully human monoclonal antibody anifrolumab failed …

